- Home
- Equipment
- north america
- antigen presenting
Show results for
Refine by
Antigen Presenting Equipment Supplied In North America
54 equipment items found
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Our exclusive iSORT (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to ...
by:Ionpath, Inc. based inMenlo Park, CALIFORNIA (USA)
Integrins mediate myeloid cell recruitment from the blood vessels into tissue and lymph nodes and contribute to the immunological synapse between T cells and antigen presenting ...
Manufactured by:Gold Standard Diagnostics based inDavis, CALIFORNIA (USA)
The Antigen Rapid Test assay from the Gold Standard Diagnostics Group is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid (N) Protein antigens present in respiratory ...
Manufactured by:Gold Standard Diagnostics based inDavis, CALIFORNIA (USA)
The GSD NovaGen SARS-CoV-2 Ag Rapid Test (Nasal Swab) is a single-use test kit intended to detect the presence of the SARS-CoV-2 virus, with self-collected nasal swab specimen from symptomatic individuals who are suspected of being infected with COVID-19. A positive result indicates SARS-CoV-2 antigens present in the ...
Manufactured by:Actym Therapeutics based inBerkeley, CALIFORNIA (USA)
In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident antigen-presenting cells. ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the antigen-presentation system (i.e. the system that presents antigen material on the surface of the tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic ...
Manufactured by:Greenwich LifeSciences, Inc. based inHouston, TEXAS (USA)
GP2 is administered in combination with GM-CSF, an FDA-approved immunoadjuvant, which stimulates the proliferation of antigen presenting ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Resistance to checkpoint inhibitor therapy has been linked to impaired immune cell infiltration into the tumor, impaired cytokine response, and deficiencies in antigen presentation including altered expression of major histocompatibility (MHC) class I complex. As a result, there is significant unmet need for novel therapeutic approaches to overcome resistance to ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Vaccination is the most cost-effective tool for the control and prevention of infectious diseases. However, multiple inoculations are often required to achieve desirable protection even with potent antigens. In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. There are several types of adjuvants with ...
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a population of mature dendritic cells. As the most potent type of antigen presenting cell in the body, dendritic cells instruct our body’s immune system to attack and eliminate harmful pathogens and unwanted cells. To target cancerous ...
Manufactured by:Universal Cells Inc. based inSeattle, WASHINGTON (USA)
The HLA Class II molecules DP, DQ and DR present peptides to CD4+ T cells and are composed of polymorphic alpha and beta chains. All Class II molecules are expressed from promoters that require the same set of transcription factors. Mutations in the transcription factors RFX5, RFXANK, RFXAP, or CIITA prevent HLA class II expression and cause Bare Lymphocyte Syndrome. Universal Donor Cells can ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
Manufactured by:NexImmune, Inc. based inGaithersburg, MARYLAND (USA)
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and bio-distribution characteristics, the AIM™ nanoparticles have the ability to engage antigen-specific T cell populations at multiple sites in the body (lymph ...
Manufactured by:VBI Vaccines Inc. based inCambridge, MASSACHUSETTS (USA)
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, virus-like particles (VLPs) are ideal for stimulating potent immune responses. VLPs can be customized to present any protein ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
Manufactured by:Boehringer Ingelheim Animal Health USA Inc. based inDuluth, GEORGIA (US) (USA)
Vetera Gold XP is a combination vaccine for horses, protecting against multiple diseases in a single 1 mL dose. It is effective for healthy horses aged 4 months or older, including pregnant mares. The vaccine protects against Eastern and Western equine encephalomyelitis (EEE & WEE), West Nile virus (WNV), tetanus, equine herpesvirus types 1 and 4 (EHV-1 & EHV-4), and equine influenza ...